American Century Companies Inc. Has $9.29 Million Holdings in Bioventus Inc. (NYSE:BVS)

American Century Companies Inc. lifted its holdings in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 38.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 884,673 shares of the company's stock after buying an additional 246,645 shares during the period. American Century Companies Inc. owned 1.09% of Bioventus worth $9,289,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Plato Investment Management Ltd bought a new stake in Bioventus in the fourth quarter valued at $38,000. Virtus Fund Advisers LLC bought a new stake in Bioventus in the 3rd quarter valued at about $42,000. Quarry LP bought a new stake in Bioventus in the 3rd quarter valued at about $59,000. Quantbot Technologies LP acquired a new position in Bioventus during the 4th quarter valued at about $103,000. Finally, Arizona State Retirement System bought a new position in Bioventus in the 4th quarter worth about $109,000. Institutional investors and hedge funds own 62.94% of the company's stock.

Bioventus Price Performance

Shares of NYSE:BVS traded down $0.06 during trading on Monday, reaching $8.27. The company had a trading volume of 587,818 shares, compared to its average volume of 436,843. The firm's fifty day moving average is $9.94 and its 200 day moving average is $10.88. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The firm has a market capitalization of $677.68 million, a PE ratio of -13.56 and a beta of 0.92. Bioventus Inc. has a twelve month low of $3.90 and a twelve month high of $14.38.

Remove Ads

Analysts Set New Price Targets

A number of research firms have recently weighed in on BVS. JPMorgan Chase & Co. raised Bioventus from an "underweight" rating to a "neutral" rating and lifted their price target for the company from $12.00 to $13.00 in a report on Tuesday, December 17th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $15.00 target price on shares of Bioventus in a research note on Monday, March 17th.

Insider Buying and Selling

In other news, CFO Mark Leonard Singleton sold 5,479 shares of Bioventus stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $9.79, for a total value of $53,639.41. Following the transaction, the chief financial officer now owns 131,963 shares of the company's stock, valued at $1,291,917.77. The trade was a 3.99 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Robert E. Claypoole sold 28,786 shares of the business's stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $9.10, for a total transaction of $261,952.60. Following the completion of the sale, the chief executive officer now owns 64,964 shares in the company, valued at $591,172.40. The trade was a 30.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 46,161 shares of company stock valued at $436,364 over the last quarter. Corporate insiders own 32.90% of the company's stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.